Global Pulmonary Drug Delivery Devices Market: Snapshot
The global market for pulmonary drug devices has gained substantially over the last few years and, with the alarming rise in the air pollution leading to the increased incidence rate of respiratory disorders, it is likely to maintain its growth at a high pace in the years to come. The increasing number of smokers across the world is also adding to the rising pool of the patients suffering from chronic obstructive pulmonary diseases (COPD), consequently benefitting the worldwide pulmonary drug delivery devices market considerably.
Going forward, the market is expected to gain significant momentum over the next few years due to the increasing research and development activities in asthma and COPD treatments. However, various regulatory hurdles and the patent expiry of blockbuster drugs may restrict the growth of this market to some extent in the near future.
The global market for pulmonary drug devices presented an opportunity worth US$32.2 bn in 2015. Propagating at a CAGR of 3.30% during the period from 2016 to 2024, the market is likely to attain a value of US$43.05 bn by the end of 2024.
North America and Europe to Continue to Lead Global Pulmonary Drug Delivery Devices Market
Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa are the main regional markets for pulmonary drug delivery devices. Of these, North America has acquired the top position and is followed closely by Europe. The increasing prevalence of COPD is the key factor behind the growth of these regional markets. Analysts expect both the markets to retain their position over the forthcoming years, thanks to the technological advancements in pulmonary drug delivery devices. The U.S. and Canada have surfaced as the key domestic markets in North America, whereas, the Europe market for pulmonary drug delivery devices is led by Germany.
On the other hand, the pulmonary drug delivery devices market in Asia Pacific, Latin America, and the Middle East and Africa are likely to present great opportunities to manufacturers in the near future due to the high incidence rate of respiratory disorders. The growing awareness among consumers and their increasing disposable income are also projected to drive these markets over the next few years.
Demand for Pulmonary Drug Delivery Devices to Remain High among Asthma Patients
Pulmonary drug delivery devices find a widespread application in the treatment of asthma, COPD, and cystic fibrosis. Among these, the demand from the asthma segment is much higher than others and is likely to remain so over the next few years, thanks to the robust pipeline of drugs for the treatment of asthma.
Some the key players operating in the global market for pulmonary drug delivery devices are Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline Plc, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., MannKind Corp., Bristol-Myers Squibb Co., Mylan N.V., Omron Corp., F. Hoffmann-La Roche Ltd., 3M Healthcare, Sunovion Pharmaceuticals Inc., Koninklijke Philips N.V., Gerresheimer AG, Bespak, AptarGroup Inc., SHL Group, Nypro Healthcare Inc., Hovione, and Chiesi Farmaceutici S.p.A.
Global Pulmonary Drug Delivery Devices Market: Overview
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drug delivery devices market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drug Delivery Devices Market: Segmentation
The global pulmonary drug delivery devices market has been studied based on major product type, application segments, major distribution channels, and regional as well as national markets. Based on product type, the global market has been categorized into three major segments: Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers. Based on application, the global market has been categorized into four segments: Asthma, COPD, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into three key segments: retail pharmacies, hospital pharmacies, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drug delivery devices market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products / applications / distribution channels / geographies.
Global Pulmonary Drug Delivery Devices Market: Regional Overview
Geographically, the pulmonary drug delivery devices market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drug delivery devices market has been further categorized into major product, application, and end-user segments considered within the scope of the study.
Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
Global Pulmonary Drug Delivery Devices Market: Competitive Outlook
The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drug delivery devices market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drug delivery devices market.
The report also profiles key players operating in the pulmonary drug delivery devices market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, 3M Healthcare, Omron Corporation, and others.
The global pulmonary drug delivery devices market has been segmented as follows:
By Product type
- Dry Powder Inhalers
- Single-dose inhalers
- Multi-dose inhalers
- Metered Dose Inhalers
- Manually-actuated pressurized inhaler
- Breath-actuated pressurized inhaler
- Jet nebulizers
- Ultrasonic wave nebulizers
- Vibrating mesh nebulizers
- Cystic Fibrosis
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa